A randomized Phase 3 study of rigosertib (ON 01910.Na) in myelodysplastic syndrome (MDS) patients who have failed or relapsed after azacitidine or decitabine treatment.

The primary purpose of this study is to compare overall survival (OS) in patients receiving rigosertib plus best supportive care (BSC) to OS of patients receiving BSC in a population of patients with MDS with excess blasts (5% to 30% bone marrow blasts) who failed Vidaza® (azacitidine) or Dacogen® (decitabine) treatment.

For more information about the ONTIME study visit: